ARDD 2020: from aging mechanisms to interventions

Mkrtchyan, Garik; Abdelmohsen, Kotb; Andreux, Pénélope; Bagdonaite, Ieva; Barzilai, Nir; Brunak, Søren; Cabreiro, Filipe; Cabo, Rafael de; Campisi, Judith; Cuervo, Ana María; Demaria, Marco; Ewald, Collin Y.; Fang, Evandro Fei; Faragher, Richard; Ferrucci, Luigi; Freund, Adam; Silva-García, Carlos Giovanni; Georgievskaya, Anastasia; Gladyshev, Vadim N.; Glass, David J.; Gorbunova, Vera; Grey, Aubrey D.N.J. de; He, Wei; Hoeijmakers, Jan H.J.; Hoffmann, Eva R.; Horvath, Steve; Houtkooper, Riekelt H.; Jensen, Majken K.; Jensen, Martin Borch; Kane, Alice E.; Kassem, Moustapha; Keizer, Peter L.J. de; Kennedy, Brian K.; Karsenty, Gérard; Lamming, Dudley W.; Lee, Kai Fu; MacAulay, Nanna; Mamoshina, Polina; Mellon, Jim; Molenaars, Marte; Moskalev, Alexey; Mund, Andreas; Niedernhofer, Laura J.; Osborne, Brenna; Pak, Heidi H.; Parkhitko, Andrey A.; Raimundo, Nuno; Rando, Thomas A.; Rasmussen, Lene Juel; Reis, Carolina Medina; Riedel, Christian G.; Franco-Romero, Anais; Schumacher, Björn; Sinclair, David; Suh, Yousin; Taub, Pam R.; Toiber, Debra; Treebak, Jonas T.; Valenzano, Dario Riccardo; Verdin, Eric; Vijg, Jan; Young, Sergey; Zhang, Lei; Bakula, Daniela; Zhavoronkov, Alex; Scheibye‐Knudsen, Morten

doi:10.18632/aging.202454

Cited by 37 publications

(37 citation statements)

References 116 publications

(122 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current interventions include genetic, pharmacological and non-pharmacological approaches or lifestyle modifications such as diet to control both nutrient intake as well as metabolic regulation and exercise [131].…”

Section: Developing Modes Of Intervention and Preventionmentioning

confidence: 99%

“…As molecular, biochemical and genomic data of both healthy and unhealthy individuals are amassed, AI uses this information to identify biomarkers or features specific to certain processes and can then establish targets to treat. Ultimately, data can be used to innovate drugs or therapy and screening techniques can streamline a patient to a proper diagnosis and eventually may even be capable of optimizing the treatment for each individual [131].…”

Section: Developing Modes Of Intervention and Preventionmentioning

confidence: 99%

See 1 more Smart Citation

Vision through Healthy Aging Eyes

Erdinest

London²,

Lavy

et al. 2021

Vision

View full text Add to dashboard Cite

As life expectancy grows, so too will the number of people adversely affected by age. Although it is acknowledged that many conditions and diseases are associated with age, this mini-review will present a current update of the various visual changes that generally occur in healthy individuals disregarding the possible effects of illness. These alterations influence how the world is perceived and in turn can affect efficiency or the ability to perform ordinary daily tasks such as driving or reading. The most common physical developments include a decreased pupil size and retinal luminance as well as changes both in intercellular and intracellular connections within the retina along the pathway to the visual cortex and within the visual cortex. The quantity and the physical location of retinal cells including photoreceptors, ganglion and bipolar retinal cells are modified. The clarity of intraocular organs, such as the intraocular lens, decreases. These all result in common visual manifestations that include reduced visual acuity, dry eyes, motility changes, a contraction of the visual field, presbyopia, reduced contrast sensitivity, slow dark adaptation, recovery from glare, variation in color vision and a decreased visual processing speed. Highlighting these prevalent issues as well as current and possible future innovations will assist providers to formulate treatments and thereby conserve maximum independence and mobility in the modern mature population.

show abstract

Section: Developing Modes Of Intervention and Preventionmentioning

confidence: 99%

Section: Developing Modes Of Intervention and Preventionmentioning

confidence: 99%

Vision through Healthy Aging Eyes

Erdinest

London²,

Lavy

et al. 2021

Vision

View full text Add to dashboard Cite

show abstract

“…Fueled by realized and anticipated market returns 83,84 , the ongoing translation from bench to bedside necessitates careful consideration of the value proposition surrounding emerging therapies in the context of extended longevity. Notably, anti-aging science increasingly aims at developing prophylactic and curative interventions, promoting a transition from traditional symptom mitigation in advanced, disabling disease toward early, proactive health management 85 .…”

Section: Economic Considerationmentioning

confidence: 99%

Longevity leap: mind the healthspan gap

2021

View full text Add to dashboard Cite

Life expectancy has increased by three decades since the mid-twentieth century. Parallel healthspan expansion has however not followed, largely impeded by the pandemic of chronic diseases afflicting a growing older population. The lag in quality of life is a recognized challenge that calls for prioritization of disease-free longevity. Contemporary communal, clinical and research trends aspiring to extend the health horizon are here outlined in the context of an evolving epidemiology. A shared action integrating public and societal endeavors with emerging interventions that target age-related multimorbidity and frailty is needed. A multidimensional buildout of a curative perspective, boosted by modern anti-senescent and regenerative technology with augmented decision making, would require dedicated resources and cost-effective validation to responsibly bridge the healthspan-lifespan gap for a future of equitable global wellbeing.

show abstract

“…selection of currently pursued and mostly preclinical therapeutic strategies and the cellular and molecular processes that are primarily targeted. The efficiency of pharmacological interventions, lifestyle strategies, gene therapies, and the clearance of senescent cells have been successfully addressed in various cellular and animal models for PSs [112][113][114]. Lonafarnib (Zokinvy) is a potent farnesyltransferase inhibitor that has been approved as a treatment for HGPS and other progeroid laminopathies by the FDA.…”

Section: Trends In Molecular Medicinementioning

confidence: 99%